Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Lung Cancer Année : 2023

Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC)

Julien Mazieres
Ali Chour
  • Fonction : Auteur
Florian Guisier
  • Fonction : Auteur
Marion Ferreira
  • Fonction : Auteur
Maxime Boussageon
  • Fonction : Auteur
Denis L. Moro-Sibilot
  • Fonction : Auteur
Jacques L. Cadranel
  • Fonction : Auteur
Gérard Zalcman
  • Fonction : Auteur
Charles Ricordel
  • Fonction : Auteur
Marie Wislez
Camille Munck
  • Fonction : Auteur
Claire Poulet
  • Fonction : Auteur
Clotilde Descarpentries
  • Fonction : Auteur
Eric Wasielewski
  • Fonction : Auteur
Alexis Benjamin Cortot
  • Fonction : Auteur
Simon Baldacci

Résumé

Background: NRAS mutations are observed in less than 1% of non-small cell lung cancer (NSCLC). Clinical data regarding this rare subset of lung cancer are scarce and response to systemic treatment such as chemotherapy or immune checkpoint inhibitors (ICI) has never been reported. Methods: All consecutive patients with an NRAS mutated NSCLC, diagnosed between August 2014 and November 2020 in 14 French centers, were included. Clinical and molecular data were collected and reviewed from medical records. Results: Out of the 164 included patients, 106 (64.6%) were men, 150 (91.5%) were current or former smokers, and 104 (63.4%) had stage IV NSCLC at diagnosis. The median age was 62 years, and the most frequent histology was adenocarcinoma (81.7%). NRAS activating mutations were mostly found in codon 61 (70%), while codon 12 and 13 alterations were observed in 16.5% and 4.9% of patients, respectively. Programmed death ligand-1 expression level <1%/1–49%/≥50% were respectively found in 30.8%/27.1%/42.1% of tumors. With a median follow-up of 12.5 months, median overall survival (OS) of stage IV patients was 15.3 months (95% CI 9.9–27.6). No significant difference in OS was found according to the type of mutation (codon 61 vs. other), HR = 1.12 (95% CI 0.65–1.95). Among stage IV patients treated with platinum-based doublet (n = 66), ICI (n = 48), or combination of both (n = 10), objective response rate, and median progression free survival were respectively 45% and 5.8 months, 35% and 6.9 months, 70% and 8.6 months. Conclusion: NRAS mutated NSCLC are characterized by a high frequency of smoking history and codon 61 mutations. Further studies are needed to confirm the encouraging outcome of immunotherapy in combination with chemotherapy.
Fichier sous embargo
Fichier sous embargo
0 1 5
Année Mois Jours
Avant la publication
samedi 1 juin 2024
Fichier sous embargo
samedi 1 juin 2024
Connectez-vous pour demander l'accès au fichier

Dates et versions

hal-04294653 , version 1 (01-12-2023)

Identifiants

Citer

Agathe Dehem, Julien Mazieres, Ali Chour, Florian Guisier, Marion Ferreira, et al.. Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC). Lung Cancer, 2023, 186, ⟨10.1016/j.lungcan.2023.107393⟩. ⟨hal-04294653⟩
17 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More